secwatch.observer — SEC 8-K summary
======================================

Issuer:     BICYCLE THERAPEUTICS PLC (BCYC)
CIK:        0001761612
Form:       8-K
Filed at:   2025-08-08T23:59:59+00:00
Accession:  0001104659-25-075435
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bicycle Therapeutics Q2 net loss widens to $1.14/share; cuts workforce 30% to extend runway
--------------------------------------------------------------------------------

- Net loss $79.0M ($1.14/share) vs $39.8M ($0.77) a year ago; R&D spend rose 77% to $71.0M.
- Cash $721.5M at June 30, down from $879.5M at Dec 31; company expects runway through 2028 after cost realignment.
- Workforce reduction of ~30% announced; Duravelo-5 trial paused while Duravelo-4 (NECTIN4-amplified NSCLC) enrolling.
- Charles Swanton appointed to Board and Scientific Committee; new Research & Innovation Advisory Board formed.
- Key catalyst: FDA meeting planned 4Q 2025 for zelenectide pevedotin accelerated approval pathway in mUC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761612/000110465925075435/0001104659-25-075435-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761612/000110465925075435/tm2522885d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-075435

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer